The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Bomedemstat combined with ruxolitinib for the treatment of MF: early results of a Phase II trial
Harinder Gill, MBBS, PDipID, MD, MRCP, FRCPath, FHKCP, FHKAM, The University of Hong Kong, Hong Kong, China, presents the early results of a Phase II study assessing the safety profile and efficacy of a combination of bomedemstat and ruxolitinib in patients with myelofibrosis (MF) (NCT05569538) who are either treatment-naïve or refractory to ruxolitinib. The ongoing study investigates the safety, tolerability, spleen size, and symptom score reduction (using the Myelofibrosis Symptom Assessment Form) in patients receiving the combination of therapies. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: BMS, Pfizer, GSK, Novartis, PharmaEssentia
Conference support: Pfizer, Novartis, PharmaEssentia
Research Funding: Imago BioSciences, Inc. (a subsidiary of Merck & Co., Inc.), Novartis, PharmaEssentia
